Business Standard

Monday, December 23, 2024 | 09:21 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Dr Reddy's gains 6% on receiving EIR from USFDA for Hyderabad facility

The stock rallied 6% to Rs 2,328 on BSE after the company announced that it has received EIR from the US drug regulator for its facility in Hyderabad following audit in April.

reddy, dr reddy's
Premium

Dr Reddy's laboratory

SI Reporter Mumbai
Dr Reddy's Laboratories rallied 6% to Rs 2,328 on BSE in early morning trade after the company announced that it has received Establishment Inspection Report (EIR) from the US drug regulator for its facility in Hyderabad following the audit in April.

“We have received EIR from the US Food and Drug Administration (USFDA) on December 11, 2017 as closure of audit, for formulations manufacturing plant-3 at Bachupally, Hyderabad,” Dr Reddy’s Laboratories said in a statement.

The above-referred facility was audited by USFDA in April 2017, wherein it issued a form 483 with 11 observations.

“These observations were

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in